Highlights From AACR IO 2026: Breaching the Tumor Microenvironment Fortress With New CAR T and Chimeras
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
In 1993, Jon R. Katzenbach and Douglas K. Smith authored The Wisdom of Teams, a collection of observations and...
Medical risks of obesity include high blood pressure, type 2 diabetes, and cardiovascular diseases. Additionally, obesity has been associated...
Compared to treatment advances for other types of cancer, progress in treating brain cancer has been frustratingly slow. Still,...
On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain...
A diverse group of about 220 physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research...
This past year has been a year of many “firsts” for the oncology community, with several revolutionary advances in...
As 2017 draws to a close, I’ve been reflecting on another year in cancer research. As Chief Executive Officer...
While Cancer Research Catalyst covers the spectrum of cancer research news, we weren’t surprised to discover that the hottest...
When we think about “cancer scientists,” we typically conjure images of physicians treating their patients or biologists analyzing cells...
Prostate cancer is one of the most common cancers diagnosed in the United States. About one-third of men diagnosed...